The Complete Guide to CAR Design & Construction



April 26, 2018

CAR-T refers to Chimeric Antigen Receptor T-Cell Immunotherapy, which is a modification of the conventional T cell receptor TCR via a chimeric antigen receptor and is generally engineered into a monoclonal antibody antigen-binding domain. In the scFV segment, the modified CAR-T cells can specifically recognize tumor-associated antigens, and are not limited by MHC, so that the targeting, killing activity, and persistence of effector T cells are improved compared with conventional immune cells. CAR-T technology generally selects cytotoxic T lymphocytes (CTLs) for modification because CTLs recognize tumor antigens and release granzymes and perforin to kill tumors.

Cancer Research

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.